# A Study of Tirzepatide in Overweight and Very Overweight Participants

> **NCT04311411** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 114 (actual)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo
- **DRUG:** Liraglutide

## Key facts

- **NCT ID:** NCT04311411
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-24
- **Primary completion:** 2022-12-16
- **Final completion:** 2022-12-16
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04311411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04311411, "A Study of Tirzepatide in Overweight and Very Overweight Participants". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04311411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*